Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Web Exclusives - Prostate Cancer, ASCO Highlights
Phoebe Starr

The addition of 177Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the ASCO 2021 virtual annual meeting.

At a median follow-up of 20.9 months, the risk for radiographic progression or death was 60% lower in patients who received 177Lu-PSMA-617 compared with those who received best standard of care alone.

“These findings warrant adoption of 177Lu-PSMA-617 as a new treatment option in patients with mCRPC, pending FDA approval,” said lead investigator Michael J. Morris, MD, Section Head, Prostate Cancer, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York City.

177Lu-PSMA-617 is one of several investigational therapies that target PSMA, which is expressed on the surface of metastatic prostate cancer cells but not on normal tissue.

Study Details

The open-label, randomized, phase 3 VISION trial included 831 patients (1179 initially screened) with progressive PSMA-positive mCRPC who had received ≥1 novel androgen receptor–directed therapies (enzalutamide [Xtandi] or abiraterone acetate [Zytiga]) and were previously treated with 1 to 2 taxane regimens.

PET imaging with 68Ga-PSMA-11 was used to determine PSMA positivity. At baseline, all patients were PSMA-positive, and demographics and disease characteristics were well-balanced. Previous treatment with radium-223 was not allowed.

Patients were randomized in a 2:1 ratio to physicians’ choice of best standard of care either with or without 4 to 6 cycles of 177Lu-PSMA-617 at a dose of 7.4 GBq every 6 weeks. The co-primary end points of the trial were overall survival (OS) and radiographic progression-free survival (PFS).

The median OS was 15.3 months in the 177Lu-PSMA-617 arm versus 11.3 months in the control arm, representing a 38% reduction in the risk for death (P <.001). The radiographic PFS was 8.7 versus 3.4 months, respectively, a 40% reduction in risk for disease progression or death (P <.001).

A statistically significant benefit was observed with 177Lu-PSMA-617 for the key secondary end points of time to first symptomatic skeletal event, objective response rate, and disease control rate. The median time to first symptomatic skeletal event was 11.5 months in the 177Lu-PSMA-617 arm compared with 6.8 months in the control arm. The objective response rates and disease control rates were 29.8% versus 1.7% and 89.0% versus 66.7%, respectively.

Safety Profile

Safety was analyzed in 529 patients in the 177Lu-PSMA-617 arm and 205 patients in the control arm. 177Lu-PSMA-617 treatment was well-tolerated. The most frequently reported adverse events (AEs) of any grade in the 177Lu-PSMA-617 arm were fatigue (49.1% vs 29.3% in the control arm), bone marrow suppression (47.4% vs 17.6%, respectively), dry mouth (39.3% vs 1%, respectively), nausea/vomiting (39.3% vs 17.1%, respectively), kidney effects (8.7% vs 5.9%, respectively), second primary malignancies (2.1% vs 1%, respectively), and intracranial bleeding (1.3% vs 1.5%, respectively).

High-grade treatment-emergent AEs were reported in 52.7% of patients in the 177Lu-PSMA-617 arm and 38% of patients were treated with standard of care alone. The most common grade 3/5 AEs associated with 177Lu-PSMA-617 were bone marrow suppression (23.4% vs 6.8% in the control arm), fatigue (7% vs 2.4%, respectively), kidney effects (3.4% vs 2.9%, respectively), and nausea/vomiting (1.5% vs 0.5%, respectively).

Expert Commentary

Commenting on the VISION trial, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, said, “This is an important study, as the patients in this trial had mCRPC, so they had disease that grew even when testosterone in the body had already been reduced to very low levels, despite receiving 1 to 2 previous taxane regimens.”

“This trial shows an alternative to traditional therapies by using radiation targeted to the PSMA antigen. So, it could be delivered directly to the prostate cancer cells, and by doing that, survival was significantly improved. Use of the PSMA radioligand therapy, if it obtains regulatory approval, could indeed become an important treatment option for these patients with refractory disease,” she added.

Related Items
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer
Seon Jo Park, PharmD, BCOP, Benjamin Yoder, PharmD, Tammy Li, PharmD
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Review Article, Prostate Cancer
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives published on October 11, 2021 in Multiple Myeloma, ASCO Highlights
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Web Exclusives published on October 4, 2021 in Biosimilars, ASCO Highlights
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Web Exclusives published on October 4, 2021 in Lung Cancer, ASCO Highlights
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in FDA Oncology Update, Prostate Cancer
FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer
JHOP - December 2020 Vol 10, No 6 published on December 22, 2020 in FDA Oncology Update, Prostate Cancer
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Enzalutamide Administration for a Nonhemodialysis Patient with Stage 4 Chronic Kidney Disease and Nonmetastatic Castration-Resistant Prostate Cancer
So Jung Uhm, PharmD, John Malamakal, PharmD, MS, BCPS, BCOP
JHOP - October 2020 Vol 10, No 5 published on October 21, 2020 in Case Reports, Kidney Disease, Dose Escalation/Reduction, Prostate Cancer
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
ASCO 2020 Lung Cancer Highlights
Conference Correspondent  published on July 30, 2020 in ASCO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.